文献速递肝病消化道肿瘤与早癌

VEPH1低表达通过削弱TSC1/TSC2结合激活肝细胞癌中的mTORC1信号

Dampened VEPH1 activates mTORC1 signaling by weakening the TSC1/TSC2 association in hepatocellular carcinoma.
PubMed 文献 · J Hepatol · 2020-06-28

该研究在肝细胞癌(HCC)组织中检测VEPH1表达并探究其功能与机制。VEPH1在HCC中常因let-7d上调而沉默,其低表达与不良预后及侵袭性表型相关。VEPH1通过增强TSC1/TSC2结合抑制mTORC1信号,雷帕霉素可抑制VEPH1敲低的促肿瘤效应。

要点

  • VEPH1在HCC组织中频繁沉默,主要因let-7d上调所致。
  • VEPH1低表达与HCC患者不良预后及侵袭性肿瘤表型相关。
  • 雷帕霉素可抑制VEPH1敲低引起的促肿瘤效应。

核心结论

  • VEPH1缺失导致HCC中mTORC1信号异常激活。
  • 雷帕霉素(或雷帕霉素类似物)可能成为VEPH1低表达HCC患者的有效治疗选择。

研究设计与样本

  • 研究采用定量逆转录PCR(92对)、蛋白质印迹(30对)和免疫染色(225例)检测HCC组织样本中VEPH1表达。
  • 通过体内外实验探究VEPH1对肿瘤生长和转移的功能影响。
  • 采用分子和生化策略探讨VEPH1抑癌功能的机制。

主要发现

  • VEPH1在HCC组织中频繁沉默,主要源于let-7d上调。
  • VEPH1表达降低与HCC患者不良预后和侵袭性肿瘤表型相关。
  • VEPH1通过调控细胞增殖、迁移和侵袭在体内外发挥抑癌活性。
  • VEPH1片段580-625aa和447-579aa分别直接结合TSC1(719-1,164aa)和TSC2(1-420aa),增强TSC1/TSC2结合并促进TSC2转位至膜,导致TSC2 Ser1387磷酸化增加。
  • 随后Rheb被TSC2的GTP酶活性失活,抑制mTORC1信号,从而影响HCC发生和转移。

临床怎么用

  • 作者认为雷帕霉素(或雷帕霉素类似物)可能作为VEPH1低表达HCC患者的有效治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Abnormal activation of mTORC1 signaling occurs at high frequency in hepatocellular carcinoma (HCC). However, the underlying causes of this aberrant activation remain elusive. In this study, we identified ventricular zone expressed pleckstrin homology domain-containing 1 (VEPH1) as a novel tumor suppressor that acts via the mTORC1 axis. METHODS: We performed quantitative reverse-transcription PCR (92 pairs), western blot (30 pairs), and immunostaining (225 cases) assays in HCC tissue samples to evaluate VEPH1 expression. We explored the functional effects of VEPH1 on tumor growth and metastasis. Molecular and biochemical strategies were used to gain insight into mechanisms underlying the tumor-suppressive function of VEPH1. RESULTS: VEPH1 is frequently silenced in HCC tissues, primarily resulting from let-7d upregulation. Decreased VEPH1 expression is associated with poor prognosis and aggressive tumor phenotypes in patients with HCC. VEPH1 mediates its tumor-suppressing activity through regulation of cell proliferation, migration and invasion in vitro and in vivo. The VEPH1 fragments 580-625aa and 447-579 aa bind directly to TSC1 (719-1,164aa) and TSC2 (1-420 aa), respectively, enhancing TSC1/TCS2 binding and promoting translocation of TSC2 to the membrane, which leads to increased TSC2 Ser1387 phosphorylation. Subsequently, Rheb is inactivated by the GTPase activity of TSC2, inhibiting mTORC1 signaling and contributing to changes in HCC carcinogenesis and metastasis. Rapamycin, the mTOR inhibitor, can inhibit the pro-tumorigenic effect of VEPH1 knockdown. Loss of VEPH1 correlates with decreased TSC2 Ser1387 phosphorylation and increased mTOR activity in HCC specimens. CONCLUSIONS: The loss of VEPH1 leads to aberrantly activated mTORC1 signaling in HCC; rapamycin (or rapalogs) may serve as an effective treatment option for patients with HCC and dampened VEPH1 expression. LAY SUMMARY: Abnormally activated mammalian target of rapamycin (mTOR) signaling is associated with poor tumor differentiation, early tumor recurrence and worse overall survival in patients with hepatocellular carcinoma. Herein, we identify low VEPH1 expression as a potential cause of abnormally activated mTOR signaling in hepatocellular carcinoma tissues. mTOR inhibitors could thus be an effective treatment option for patients with HCC and low VEPH1 expression.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Dong P, Wang X, Liu L, et al. Dampened VEPH1 activates mTORC1 signaling by weakening the TSC1/TSC2 association in hepatocellular carcinoma. J Hepatol. 2020. PMID: 32610114. doi:10.1016/j.jhep.2020.06.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。